Falkenberg, Virginia R, Gurbaxani, Brian M, Unger, Elizabeth R et al. · Neuromolecular medicine · 2011 · DOI
This study looked at how a specific genetic variation in the serotonin receptor 2A gene (HTR2A) affects how active this gene is in people with ME/CFS. The researchers found that this gene is turned up (overactive) in ME/CFS patients, and that this overactivity is influenced by both the genetic variant someone inherits and how stress hormones like cortisol affect the gene's activity. Think of it like a volume knob on a radio that can be turned up or down depending on your genes and stress levels.
Understanding how genetic variation and epigenetic changes control serotonin receptor expression in ME/CFS may help explain serotonin-related symptoms like mood changes and pain sensitivity, and could identify individuals who might respond to targeted therapies. This work demonstrates how a single genetic variant can have complex effects on gene regulation when combined with stress hormones and chemical modifications to DNA, offering insights into personalized treatment approaches.
This study does not prove that the HTR2A polymorphism or serotonin dysfunction is the primary cause of ME/CFS—it only shows an association in gene expression patterns. The findings are correlational and based on a single population, so causality cannot be established and results must be validated in other independent ME/CFS cohorts before clinical application. Cross-sectional data cannot determine whether altered HTR2A expression is a cause or consequence of the disease.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →